Antares Pharma, Inc. announced that a Type A meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 21, 2018 for XYOSTED™, the Company’s investigational new drug for the treatment of testosterone deficiency (hypogonadism). The request for a meeting was in response to the Complete Response Letter received by Antares regarding the New Drug Application (NDA) for XYOSTED™. The Company intends to provide an update on the outcome of the Type A meeting following receipt of the FDA generated minutes, which are typically received within thirty days of the meeting.